Medicine in Drug Discovery (Dec 2023)
Lipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics
Abstract
Among all diseases, cancer has the highest fatality rate in the world. Conventional therapies have come a long way, but they still are not a panacea for cancer. Nanotechnology-based compositions of several nanoparticles (NPs) hold promise as a cancer therapy. The co-delivery of amphiphilic molecules is feasible with lipid-polymer hybrid nanoparticles (LPHNPs). Increased encapsulation of pharmaceuticals with a regulated release profile is made possible by the physical benefits of polymers and the resembling features of lipids. For increased cytotoxicity against cancer, LPHNPs have been created for the co-transport of phytochemicals and other chemotherapeutic medicines. Specifically, LPHNPs are used as carrier systems to deliver drugs to tumour locations in a regulated fashion. This method makes use of the biocompatibility of lipids and the structural advantages of polymers to provide controlled drug administration. Co-loaded LPHNPs demonstrated improved cytotoxicity, and the incorporation of phytochemicals into various medications resulted in enhanced chemo-sensitization of carcinomas. The shortcomings of existing nano-delivery systems and the benefits of LPHNPs have been discussed in this review.